| Dr Edward Anthony Wingfield, MD | |
|
2073 Klockner Rd, Hamilton, NJ 08690-3414 | |
| (609) 584-1212 | |
| (609) 584-0103 |
| Full Name | Dr Edward Anthony Wingfield |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 21 Years |
| Location | 2073 Klockner Rd, Hamilton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164606034 | NPI | - | NPPES |
| 0233846 | Medicaid | NJ | |
| 22-3052989 | Other | NJ | TAX ID |
| Facility Name | Location | Facility Type |
|---|---|---|
| Robert Wood Johnson University Hospital At Hamilton | Hamilton, NJ | Hospital |
| Capital Health Medical Center - Hopewell | Pennington, NJ | Hospital |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hamilton Cardiology Associates Pa | 4284629932 | 19 |
News Archive
From 1997 to 2007, the rates of visits to emergency departments in the U.S. increased significantly, particularly among adults with Medicaid, according to a study in the August 11 issue of JAMA.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
With states confronting a weakening economy, enrollment in Medicaid began to rise last year with states expecting even larger increases for fiscal year 2009, according to a new 50-state survey released today by the Kaiser Family Foundation's Kaiser Commission on Medicaid and the Uninsured (KCMU). With the increased enrollment, Medicaid spending is also rising more rapidly than in the recent past, raising the potential for program cutbacks as states confront the combined impact of more enrollees and fewer available resources.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 2 days ago
| Entity Name | Hamilton Cardiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326026378 PECOS PAC ID: 4284629932 Enrollment ID: O20040420000887 |
News Archive
From 1997 to 2007, the rates of visits to emergency departments in the U.S. increased significantly, particularly among adults with Medicaid, according to a study in the August 11 issue of JAMA.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
With states confronting a weakening economy, enrollment in Medicaid began to rise last year with states expecting even larger increases for fiscal year 2009, according to a new 50-state survey released today by the Kaiser Family Foundation's Kaiser Commission on Medicaid and the Uninsured (KCMU). With the increased enrollment, Medicaid spending is also rising more rapidly than in the recent past, raising the potential for program cutbacks as states confront the combined impact of more enrollees and fewer available resources.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 2 days ago
| Entity Name | Princeton Healthcare Provider Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699141507 PECOS PAC ID: 3173824695 Enrollment ID: O20151228002256 |
News Archive
From 1997 to 2007, the rates of visits to emergency departments in the U.S. increased significantly, particularly among adults with Medicaid, according to a study in the August 11 issue of JAMA.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
With states confronting a weakening economy, enrollment in Medicaid began to rise last year with states expecting even larger increases for fiscal year 2009, according to a new 50-state survey released today by the Kaiser Family Foundation's Kaiser Commission on Medicaid and the Uninsured (KCMU). With the increased enrollment, Medicaid spending is also rising more rapidly than in the recent past, raising the potential for program cutbacks as states confront the combined impact of more enrollees and fewer available resources.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward Anthony Wingfield, MD 45 Foxchase Drive., Burlington, NJ 08016 Ph: (609) 387-5119 | Dr Edward Anthony Wingfield, MD 2073 Klockner Rd, Hamilton, NJ 08690-3414 Ph: (609) 584-1212 |
News Archive
From 1997 to 2007, the rates of visits to emergency departments in the U.S. increased significantly, particularly among adults with Medicaid, according to a study in the August 11 issue of JAMA.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
With states confronting a weakening economy, enrollment in Medicaid began to rise last year with states expecting even larger increases for fiscal year 2009, according to a new 50-state survey released today by the Kaiser Family Foundation's Kaiser Commission on Medicaid and the Uninsured (KCMU). With the increased enrollment, Medicaid spending is also rising more rapidly than in the recent past, raising the potential for program cutbacks as states confront the combined impact of more enrollees and fewer available resources.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
› Verified 2 days ago
Mrs. Ebele Edith Ufondu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 941 Whitehorse Avenue, Suite 14, Hamilton, NJ 08610 Phone: 609-581-4800 Fax: 609-581-9980 | |
Dr. Ali Raza, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1235 Whitehorse Mercerville Rd, Suite 306, Hamilton, NJ 08619 Phone: 609-581-9000 | |
John Stabile, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Whitehorse Mercerville Rd Ste 218, Hamilton, NJ 08619 Phone: 609-689-5760 Fax: 609-689-5759 | |
Adam Lucas, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2073 Klockner Rd, Hamilton, NJ 08690 Phone: 609-584-1212 Fax: 609-584-0103 | |
Dr. Marcella M. Frank, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1401 Whitehourse-mercerville Road, Suite 219, Hamilton, NJ 08619 Phone: 609-584-5150 Fax: 602-584-5144 | |
Dr. Neerja Misra, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2279 Highway 33 Ste 518, Hamilton, NJ 08690 Phone: 609-689-9001 Fax: 609-689-9002 | |
Dr. Akbar H Obaray, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2069 Klockner Rd, Hamilton, NJ 08690 Phone: 609-586-0031 Fax: 609-586-0708 |